Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00933933 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Diagnostic HIV Ag/Ab Combo Assay
A Phase 3 study, sponsored by Abbott Diagnostics Division.
- Completed
- Registry status
- Phase 3
- Development phase
- 635
- Enrollment target
NCT00933933: Completed Phase 3 study, sponsored by Abbott Diagnostics Division.
NCT00933933 is a Phase 3 study that has completed, run by Abbott Diagnostics Division. The registered enrollment target is 635 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (18% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00933933, a Phase 3 study, has completed, sponsored by Abbott Diagnostics Division.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 635 participants
- Enrollment target
Study Summary
To test blood specimens using a new investigational test that detects antigen and antibody to human immunodeficiency virus (HIV). Results will be compared to an approved HIV antibody test and supplemental testing performed to determine HIV status.
Primary Outcome
HIV status was determined by the results of the HIV comparator assay, HIV-1 Western blot, HIV-2 Western blot, and HIV-1 ribonucleic acid (RNA) test.
Interventions
- DEVICE ARCHITECT HIV Ag/Ab Combo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 635 participants |
| Start Date | 2009-06 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
What the finished NCT00933933 record still lists
NCT00933933 is an interventional study that assigns participants to a tested intervention. The registered 635 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (18% lower).
The record links to 0 conditions, and to 1 intervention - of which ARCHITECT HIV Ag/Ab Combo is the first listed.
NCT00933933 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00933933 about?
NCT00933933 is a clinical study titled "Evaluation of Diagnostic HIV Ag/Ab Combo Assay". To test blood specimens using a new investigational test that detects antigen and antibody to human immunodeficiency virus (HIV). Results will be compared to an approved HIV antibody test and supplemental testing performed to determine HIV status.
What is the current status of trial NCT00933933?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 635 participants. The study started on 2009-06. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00933933?
The interventions under investigation include: ARCHITECT HIV Ag/Ab Combo (DEVICE).
Who is sponsoring clinical trial NCT00933933?
This trial is sponsored by Abbott Diagnostics Division, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00933933's enrollment target sits among peer trials
635 579th of 2000 higher than 1,422 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03478826 · 635 participants
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
- NCT03821129 · 636 participants · NA
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
- NCT00573027 · 634 participants · NA
Heart Disease of the Small Arteries in Women and Men
- NCT04108156 · 634 participants · Phase 3
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia